<?xml version="1.0" encoding="utf-8"?>
<feed xmlns:pubs="http://www.symplectic.co.uk/publications/atom-api" xmlns="http://www.w3.org/2005/Atom">
  <category scheme="http://www.symplectic.co.uk/publications/atom-terms/1.0" term="http://www.symplectic.co.uk/publications/atom-terms/1.0/publication" label="Publication" />
  <id>tag:elements@emory/publication/873965</id>
  <pubs:id>873965</pubs:id>
  <updated>2014-09-04T12:28:06.427-04:00</updated>
  <pubs:published>2014-07-02T11:19:41.257-04:00</pubs:published>
  <category scheme="http://www.symplectic.co.uk/publications/atom-terms/1.0" term="http://www.symplectic.co.uk/publications/atom-terms/1.0/journal-article" label="journal article" />
  <generator uri="https://profiles-dev.emory.edu/" version="4.10" id="tag:elements@emory" repository-tools-version="1.1">Emory Profiles</generator>
  <icon>http://symappdev1.cc.emory.edu:9090/publications-atom/symplectic.ico</icon>
  <rights>You are about to access an Emory University computer system that is intended for authorized users only. Unauthorized use of this system is strictly prohibited and may be subject to criminal prosecution. By proceeding, your use of this system constitutes your consent to monitoring, retrieval, and disclosure of any information within this system for any purpose deemed appropriate by Emory University, including law enforcement purposes and enforcement of rules concerning unacceptable uses of this system.</rights>
  <subtitle>This feed presents a single full publication record.</subtitle>
  <title>Profiles publication record</title>
  <pubs:organisational-details>
    <pubs:group org-id="1">/Emory University</pubs:group>
    <pubs:group org-id="2">/Emory University/School of Medicine</pubs:group>
    <pubs:group org-id="58">/Emory University/School of Medicine/Department of Hematology and Medical Oncology</pubs:group>
    <pubs:group org-id="103">/Emory University/School of Medicine/Department of Hematology and Medical Oncology/BMT</pubs:group>
  </pubs:organisational-details>
  <pubs:users>
    <pubs:user>
      <pubs:id>3674</pubs:id>
      <pubs:username>EWALLER</pubs:username>
      <pubs:authority>Shibboleth</pubs:authority>
      <pubs:proprietary-id>P5699430</pubs:proprietary-id>
      <pubs:is-current-staff>true</pubs:is-current-staff>
      <pubs:is-login-allowed>true</pubs:is-login-allowed>
      <pubs:is-academic>true</pubs:is-academic>
      <pubs:title />
      <pubs:initials>EK</pubs:initials>
      <pubs:last-name>Waller</pubs:last-name>
      <pubs:first-name>Edmund</pubs:first-name>
      <pubs:email-address>ewaller@emory.edu</pubs:email-address>
      <pubs:preferences>
        <pubs:visible>true</pubs:visible>
        <pubs:data-source>web-of-science</pubs:data-source>
        <pubs:favourite>false</pubs:favourite>
      </pubs:preferences>
      <pubs:generic-field-01>K.</pubs:generic-field-01>
      <pubs:generic-field-02>0035311</pubs:generic-field-02>
    </pubs:user>
  </pubs:users>
  <pubs:actors>
    <pubs:user type="owner">
      <pubs:id>3674</pubs:id>
      <pubs:username>EWALLER</pubs:username>
      <pubs:authority>Shibboleth</pubs:authority>
      <pubs:proprietary-id>P5699430</pubs:proprietary-id>
      <pubs:is-current-staff>true</pubs:is-current-staff>
      <pubs:title />
      <pubs:initials>EK</pubs:initials>
      <pubs:last-name>Waller</pubs:last-name>
      <pubs:first-name>Edmund</pubs:first-name>
      <pubs:email-address>ewaller@emory.edu</pubs:email-address>
    </pubs:user>
    <pubs:user type="impersonator">
      <pubs:id>6632</pubs:id>
      <pubs:username>fpici</pubs:username>
      <pubs:authority>EmoryShibboleth</pubs:authority>
      <pubs:proprietary-id>P6235048</pubs:proprietary-id>
      <pubs:is-current-staff>true</pubs:is-current-staff>
      <pubs:title />
      <pubs:initials />
      <pubs:last-name>Pici</pubs:last-name>
      <pubs:first-name>Frances Anne</pubs:first-name>
      <pubs:email-address>fpici@emory.edu</pubs:email-address>
    </pubs:user>
  </pubs:actors>
  <pubs:file-upload>
    <pubs:file-version>   Submitted version</pubs:file-version>
  </pubs:file-upload>
  <pubs:people>
    <pubs:person>
      <pubs:id>3674</pubs:id>
      <pubs:username>EWALLER</pubs:username>
      <pubs:authority>Shibboleth</pubs:authority>
      <pubs:proprietary-id>P5699430</pubs:proprietary-id>
      <pubs:is-current-staff>true</pubs:is-current-staff>
      <pubs:is-login-allowed>true</pubs:is-login-allowed>
      <pubs:is-academic>true</pubs:is-academic>
      <pubs:title />
      <pubs:initials>EK</pubs:initials>
      <pubs:last-name>Waller</pubs:last-name>
      <pubs:first-name>Edmund</pubs:first-name>
      <pubs:email-address>ewaller@emory.edu</pubs:email-address>
      <pubs:relationships>
        <pubs:relationship type="publication-user-authorship">
          <pubs:user-preferences>
            <pubs:visible>true</pubs:visible>
            <pubs:data-source>web-of-science</pubs:data-source>
            <pubs:favourite>false</pubs:favourite>
          </pubs:user-preferences>
        </pubs:relationship>
      </pubs:relationships>
      <pubs:generic-field-01>K.</pubs:generic-field-01>
      <pubs:generic-field-02>0035311</pubs:generic-field-02>
    </pubs:person>
  </pubs:people>
  <pubs:grants />
  <pubs:fields>
    <pubs:field name="requested-embargo-period" type="text" display-name="requested-embargo-period">
      <pubs:text>No embargo</pubs:text>
    </pubs:field>
    <pubs:field name="fulltext-comment" type="text" display-name="fulltext-comment">
      <pubs:text>Test Hossain</pubs:text>
    </pubs:field>
    <pubs:field name="repository-licence-id" type="integer" display-name="repository-licence-id">
      <pubs:integer>1</pubs:integer>
    </pubs:field>
  </pubs:fields>
  <pubs:all-labels type="keyword-list">
    <pubs:keywords>
      <pubs:keyword origin="record-data" source="wos">Science &amp; Technology</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">Multidisciplinary Sciences</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">Science &amp; Technology - Other Topics</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">MULTIDISCIPLINARY SCIENCES</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">VERSUS-HOST-DISEASE</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">MURINE CYTOMEGALOVIRUS-INFECTION</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">BONE-MARROW TRANSPLANTATION</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">NATURAL-KILLER-CELLS</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">IFN-GAMMA PRODUCTION</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">VIRUS-INFECTION</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">ANTIVIRAL IMMUNITY</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">VIRAL-INFECTIONS</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">ACTIVATION</pubs:keyword>
      <pubs:keyword origin="record-data" source="wos">RESPONSES</pubs:keyword>
      <pubs:keyword is-mesh="false" scheme="science-metrix" origin="issn-inferred">General Science &amp; Technology</pubs:keyword>
      <pubs:keyword is-mesh="false" scheme="for" origin="issn-inferred">MD Multidisciplinary</pubs:keyword>
    </pubs:keywords>
  </pubs:all-labels>
  <entry>
    <id>tag:elements@emory/publication/873965/bib-record/web-of-science</id>
    <pubs:data-source>
      <pubs:source-name>web-of-science</pubs:source-name>
      <pubs:id-at-source>WOS:000338101500006</pubs:id-at-source>
    </pubs:data-source>
    <pubs:verification-status>unverified</pubs:verification-status>
    <category scheme="http://www.symplectic.co.uk/publications/atom-terms/1.0" term="http://www.symplectic.co.uk/publications/atom-terms/1.0/publication-bib-record" label="Publication Bibliographic Record" />
    <author>
      <name>EK Waller</name>
    </author>
    <link rel="author-url" href="http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=PARTNER_APP&amp;SrcAuth=LinksAMR&amp;KeyUT=000338101500006&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=26b1d2830af64ebf721d972c41b398ba" />
    <title>Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice</title>
    <updated>2014-09-04T12:28:06.427-04:00</updated>
    <pubs:bibliographic-data format="native">
      <pubs:native>
        <pubs:field name="authors" type="person-list" display-name="Authors">
          <pubs:people>
            <pubs:person>
              <pubs:last-name>Hossain</pubs:last-name>
              <pubs:initials>MS</pubs:initials>
              <pubs:address>
                <pubs:line>Emory University</pubs:line>
                <pubs:line>Sch Med</pubs:line>
                <pubs:line>Dept Hematol &amp; Med Oncol</pubs:line>
                <pubs:line>Winship Canc Inst,Div Stem Cell &amp; Bone Marrow Tra</pubs:line>
                <pubs:line>Atlanta</pubs:line>
                <pubs:line>GA</pubs:line>
                <pubs:line>USA</pubs:line>
                <pubs:line>30322</pubs:line>
              </pubs:address>
              <pubs:addresses>
                <pubs:address>
                  <pubs:line>Emory University</pubs:line>
                  <pubs:line>Sch Med</pubs:line>
                  <pubs:line>Dept Hematol &amp; Med Oncol</pubs:line>
                  <pubs:line>Winship Canc Inst,Div Stem Cell &amp; Bone Marrow Tra</pubs:line>
                  <pubs:line>Atlanta</pubs:line>
                  <pubs:line>GA</pubs:line>
                  <pubs:line>USA</pubs:line>
                  <pubs:line>30322</pubs:line>
                </pubs:address>
              </pubs:addresses>
            </pubs:person>
            <pubs:person>
              <pubs:last-name>Ramachandiran</pubs:last-name>
              <pubs:initials>S</pubs:initials>
              <pubs:address>
                <pubs:line>Emory University</pubs:line>
                <pubs:line>Sch Med</pubs:line>
                <pubs:line>Dept Hematol &amp; Med Oncol</pubs:line>
                <pubs:line>Winship Canc Inst,Div Stem Cell &amp; Bone Marrow Tra</pubs:line>
                <pubs:line>Atlanta</pubs:line>
                <pubs:line>GA</pubs:line>
                <pubs:line>USA</pubs:line>
                <pubs:line>30322</pubs:line>
              </pubs:address>
              <pubs:addresses>
                <pubs:address>
                  <pubs:line>Emory University</pubs:line>
                  <pubs:line>Sch Med</pubs:line>
                  <pubs:line>Dept Hematol &amp; Med Oncol</pubs:line>
                  <pubs:line>Winship Canc Inst,Div Stem Cell &amp; Bone Marrow Tra</pubs:line>
                  <pubs:line>Atlanta</pubs:line>
                  <pubs:line>GA</pubs:line>
                  <pubs:line>USA</pubs:line>
                  <pubs:line>30322</pubs:line>
                </pubs:address>
              </pubs:addresses>
            </pubs:person>
            <pubs:person>
              <pubs:last-name>Gewirtz</pubs:last-name>
              <pubs:initials>AT</pubs:initials>
              <pubs:address>
                <pubs:line>Georgia State University</pubs:line>
                <pubs:line>Dept Biol</pubs:line>
                <pubs:line>Atlanta</pubs:line>
                <pubs:line>GA</pubs:line>
                <pubs:line>USA</pubs:line>
              </pubs:address>
              <pubs:addresses>
                <pubs:address>
                  <pubs:line>Georgia State University</pubs:line>
                  <pubs:line>Dept Biol</pubs:line>
                  <pubs:line>Atlanta</pubs:line>
                  <pubs:line>GA</pubs:line>
                  <pubs:line>USA</pubs:line>
                </pubs:address>
              </pubs:addresses>
            </pubs:person>
            <pubs:person>
              <pubs:last-name>Waller</pubs:last-name>
              <pubs:initials>EK</pubs:initials>
              <pubs:address>
                <pubs:line>Emory University</pubs:line>
                <pubs:line>Sch Med</pubs:line>
                <pubs:line>Dept Hematol &amp; Med Oncol</pubs:line>
                <pubs:line>Winship Canc Inst,Div Stem Cell &amp; Bone Marrow Tra</pubs:line>
                <pubs:line>Atlanta</pubs:line>
                <pubs:line>GA</pubs:line>
                <pubs:line>USA</pubs:line>
                <pubs:line>30322</pubs:line>
              </pubs:address>
              <pubs:addresses>
                <pubs:address>
                  <pubs:line>Emory University</pubs:line>
                  <pubs:line>Sch Med</pubs:line>
                  <pubs:line>Dept Hematol &amp; Med Oncol</pubs:line>
                  <pubs:line>Winship Canc Inst,Div Stem Cell &amp; Bone Marrow Tra</pubs:line>
                  <pubs:line>Atlanta</pubs:line>
                  <pubs:line>GA</pubs:line>
                  <pubs:line>USA</pubs:line>
                  <pubs:line>30322</pubs:line>
                </pubs:address>
              </pubs:addresses>
            </pubs:person>
          </pubs:people>
        </pubs:field>
        <pubs:field name="author-url" type="text" display-name="Author URL">
          <pubs:text>http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=PARTNER_APP&amp;SrcAuth=LinksAMR&amp;KeyUT=000338101500006&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=26b1d2830af64ebf721d972c41b398ba</pubs:text>
        </pubs:field>
        <pubs:field name="doi" type="text" display-name="DOI">
          <pubs:text>10.1371/journal.pone.0096165</pubs:text>
        </pubs:field>
        <pubs:field name="issn" type="text" display-name="ISSN">
          <pubs:text>1932-6203</pubs:text>
        </pubs:field>
        <pubs:field name="issue" type="text" display-name="Issue">
          <pubs:text>5</pubs:text>
        </pubs:field>
        <pubs:field name="journal" type="text" display-name="Journal">
          <pubs:text>PLOS ONE</pubs:text>
        </pubs:field>
        <pubs:field name="keywords" type="keyword-list" display-name="Keywords">
          <pubs:keywords>
            <pubs:keyword>Science &amp; Technology</pubs:keyword>
            <pubs:keyword>Multidisciplinary Sciences</pubs:keyword>
            <pubs:keyword>Science &amp; Technology - Other Topics</pubs:keyword>
            <pubs:keyword>MULTIDISCIPLINARY SCIENCES</pubs:keyword>
            <pubs:keyword>VERSUS-HOST-DISEASE</pubs:keyword>
            <pubs:keyword>MURINE CYTOMEGALOVIRUS-INFECTION</pubs:keyword>
            <pubs:keyword>BONE-MARROW TRANSPLANTATION</pubs:keyword>
            <pubs:keyword>NATURAL-KILLER-CELLS</pubs:keyword>
            <pubs:keyword>IFN-GAMMA PRODUCTION</pubs:keyword>
            <pubs:keyword>VIRUS-INFECTION</pubs:keyword>
            <pubs:keyword>ANTIVIRAL IMMUNITY</pubs:keyword>
            <pubs:keyword>VIRAL-INFECTIONS</pubs:keyword>
            <pubs:keyword>ACTIVATION</pubs:keyword>
            <pubs:keyword>RESPONSES</pubs:keyword>
          </pubs:keywords>
        </pubs:field>
        <pubs:field name="language" type="text" display-name="Language">
          <pubs:text>English</pubs:text>
        </pubs:field>
        <pubs:field name="number" type="text" display-name="Article number">
          <pubs:text>ARTN e96165</pubs:text>
        </pubs:field>
        <pubs:field name="pagination" type="pagination" display-name="Pagination">
          <pubs:pagination>
            <pubs:page-count>12</pubs:page-count>
          </pubs:pagination>
        </pubs:field>
        <pubs:field name="publication-date" type="date" display-name="Publication date">
          <pubs:date>
            <pubs:day>30</pubs:day>
            <pubs:month>5</pubs:month>
            <pubs:year>2014</pubs:year>
          </pubs:date>
        </pubs:field>
        <pubs:field name="publication-status" type="text" display-name="Status">
          <pubs:text>Published</pubs:text>
        </pubs:field>
        <pubs:field name="publisher" type="text" display-name="Publisher">
          <pubs:text>PUBLIC LIBRARY SCIENCE</pubs:text>
        </pubs:field>
        <pubs:field name="title" type="text" display-name="Title">
          <pubs:text>Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice</pubs:text>
        </pubs:field>
        <pubs:field name="types" type="list" display-name="Sub types">
          <pubs:items>
            <pubs:item>Article</pubs:item>
            <pubs:item>Journal</pubs:item>
          </pubs:items>
        </pubs:field>
        <pubs:field name="volume" type="text" display-name="Volume">
          <pubs:text>9</pubs:text>
        </pubs:field>
      </pubs:native>
    </pubs:bibliographic-data>
  </entry>
  <entry>
    <id>tag:elements@emory/publication/873965/bib-record/pubmed</id>
    <pubs:data-source>
      <pubs:source-name>pubmed</pubs:source-name>
      <pubs:id-at-source>24879439</pubs:id-at-source>
    </pubs:data-source>
    <pubs:verification-status>unverified</pubs:verification-status>
    <category scheme="http://www.symplectic.co.uk/publications/atom-terms/1.0" term="http://www.symplectic.co.uk/publications/atom-terms/1.0/publication-bib-record" label="Publication Bibliographic Record" />
    <author>
      <name>EK Waller</name>
    </author>
    <link rel="author-url" href="http://www.ncbi.nlm.nih.gov/pubmed/24879439" />
    <title>Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice.</title>
    <summary>Prior work using allogeneic bone marrow transplantation (allo-BMT) models showed that peritransplant administration of flagellin, a toll-like receptor 5 (TLR5) agonist protected murine allo-BMT recipients from CMV infection while limiting graft-vs-host disease (GvHD). However, the mechanism by which flagellin-TLR5 interaction promotes anti-CMV immunity was not defined. Here, we investigated the anti-CMV immunity of NK cells in C57BL/6 (B6) mice treated with a highly purified cGMP grade recombinant flagellin variant CBLB502 (rflagellin) followed by murine CMV (mCMV) infection. A single dose of rflagellin administered to mice between 48 to 72 hours prior to MCMV infection resulted in optimal protection from mCMV lethality. Anti-mCMV immunity in rflagellin-treated mice correlated with a significantly reduced liver viral load and increased numbers of Ly49H+ and Ly49D+ activated cytotoxic NK cells. Additionally, the increased anti-mCMV immunity of NK cells was directly correlated with increased numbers of IFN-γ, granzyme B- and CD107a producing NK cells following mCMV infection. rFlagellin-induced anti-mCMV immunity was TLR5-dependent as rflagellin-treated TLR5 KO mice had ∼10-fold increased liver viral load compared with rflagellin-treated WT B6 mice. However, the increased anti-mCMV immunity of NK cells in rflagellin-treated mice is regulated indirectly as mouse NK cells do not express TLR5. Collectively, these data suggest that rflagellin treatment indirectly leads to activation of NK cells, which may be an important adjunct benefit of administering rflagellin in allo-BMT recipients.</summary>
    <updated>2014-09-04T12:28:06.427-04:00</updated>
    <pubs:bibliographic-data format="native">
      <pubs:native>
        <pubs:field name="abstract" type="text" display-name="Abstract">
          <pubs:text>Prior work using allogeneic bone marrow transplantation (allo-BMT) models showed that peritransplant administration of flagellin, a toll-like receptor 5 (TLR5) agonist protected murine allo-BMT recipients from CMV infection while limiting graft-vs-host disease (GvHD). However, the mechanism by which flagellin-TLR5 interaction promotes anti-CMV immunity was not defined. Here, we investigated the anti-CMV immunity of NK cells in C57BL/6 (B6) mice treated with a highly purified cGMP grade recombinant flagellin variant CBLB502 (rflagellin) followed by murine CMV (mCMV) infection. A single dose of rflagellin administered to mice between 48 to 72 hours prior to MCMV infection resulted in optimal protection from mCMV lethality. Anti-mCMV immunity in rflagellin-treated mice correlated with a significantly reduced liver viral load and increased numbers of Ly49H+ and Ly49D+ activated cytotoxic NK cells. Additionally, the increased anti-mCMV immunity of NK cells was directly correlated with increased numbers of IFN-γ, granzyme B- and CD107a producing NK cells following mCMV infection. rFlagellin-induced anti-mCMV immunity was TLR5-dependent as rflagellin-treated TLR5 KO mice had ∼10-fold increased liver viral load compared with rflagellin-treated WT B6 mice. However, the increased anti-mCMV immunity of NK cells in rflagellin-treated mice is regulated indirectly as mouse NK cells do not express TLR5. Collectively, these data suggest that rflagellin treatment indirectly leads to activation of NK cells, which may be an important adjunct benefit of administering rflagellin in allo-BMT recipients.</pubs:text>
        </pubs:field>
        <pubs:field name="authors" type="person-list" display-name="Authors">
          <pubs:people>
            <pubs:person>
              <pubs:last-name>Hossain</pubs:last-name>
              <pubs:initials>MS</pubs:initials>
              <pubs:address>
                <pubs:line>Department of Hematology and Medical Oncology, Division of Stem Cell and Bone Marrow Transplantation, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States of America.</pubs:line>
              </pubs:address>
              <pubs:addresses>
                <pubs:address>
                  <pubs:line>Department of Hematology and Medical Oncology, Division of Stem Cell and Bone Marrow Transplantation, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States of America.</pubs:line>
                </pubs:address>
              </pubs:addresses>
            </pubs:person>
            <pubs:person>
              <pubs:last-name>Ramachandiran</pubs:last-name>
              <pubs:initials>S</pubs:initials>
              <pubs:address>
                <pubs:line>Department of Hematology and Medical Oncology, Division of Stem Cell and Bone Marrow Transplantation, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States of America.</pubs:line>
              </pubs:address>
              <pubs:addresses>
                <pubs:address>
                  <pubs:line>Department of Hematology and Medical Oncology, Division of Stem Cell and Bone Marrow Transplantation, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States of America.</pubs:line>
                </pubs:address>
              </pubs:addresses>
            </pubs:person>
            <pubs:person>
              <pubs:last-name>Gewirtz</pubs:last-name>
              <pubs:initials>AT</pubs:initials>
              <pubs:address>
                <pubs:line>Department of Biology, Georgia State University, Atlanta, Georgia, United States of America.</pubs:line>
              </pubs:address>
              <pubs:addresses>
                <pubs:address>
                  <pubs:line>Department of Biology, Georgia State University, Atlanta, Georgia, United States of America.</pubs:line>
                </pubs:address>
              </pubs:addresses>
            </pubs:person>
            <pubs:person>
              <pubs:last-name>Waller</pubs:last-name>
              <pubs:initials>EK</pubs:initials>
              <pubs:address>
                <pubs:line>Department of Hematology and Medical Oncology, Division of Stem Cell and Bone Marrow Transplantation, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States of America.</pubs:line>
              </pubs:address>
              <pubs:addresses>
                <pubs:address>
                  <pubs:line>Department of Hematology and Medical Oncology, Division of Stem Cell and Bone Marrow Transplantation, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States of America.</pubs:line>
                </pubs:address>
              </pubs:addresses>
            </pubs:person>
          </pubs:people>
        </pubs:field>
        <pubs:field name="author-url" type="text" display-name="Author URL">
          <pubs:text>http://www.ncbi.nlm.nih.gov/pubmed/24879439</pubs:text>
        </pubs:field>
        <pubs:field name="doi" type="text" display-name="DOI">
          <pubs:text>10.1371/journal.pone.0096165</pubs:text>
        </pubs:field>
        <pubs:field name="eissn" type="text" display-name="eISSN">
          <pubs:text>1932-6203</pubs:text>
        </pubs:field>
        <pubs:field name="external-identifiers" type="identifier-list" display-name="External identifiers">
          <pubs:identifiers>
            <pubs:identifier scheme="pmc">PMC4039429</pubs:identifier>
          </pubs:identifiers>
        </pubs:field>
        <pubs:field name="issue" type="text" display-name="Issue">
          <pubs:text>5</pubs:text>
        </pubs:field>
        <pubs:field name="journal" type="text" display-name="Journal">
          <pubs:text>PLoS One</pubs:text>
        </pubs:field>
        <pubs:field name="language" type="text" display-name="Language">
          <pubs:text>eng</pubs:text>
        </pubs:field>
        <pubs:field name="location" type="text" display-name="Country">
          <pubs:text>United States</pubs:text>
        </pubs:field>
        <pubs:field name="pagination" type="pagination" display-name="Pagination">
          <pubs:pagination>
            <pubs:begin-page>e96165</pubs:begin-page>
          </pubs:pagination>
        </pubs:field>
        <pubs:field name="pii" type="text" display-name="PII">
          <pubs:text>PONE-D-13-50985</pubs:text>
        </pubs:field>
        <pubs:field name="publication-date" type="date" display-name="Publication date">
          <pubs:date>
            <pubs:year>2014</pubs:year>
          </pubs:date>
        </pubs:field>
        <pubs:field name="title" type="text" display-name="Title">
          <pubs:text>Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice.</pubs:text>
        </pubs:field>
        <pubs:field name="types" type="list" display-name="Sub types">
          <pubs:items>
            <pubs:item>Journal Article</pubs:item>
            <pubs:item>Research Support, N.I.H., Extramural</pubs:item>
          </pubs:items>
        </pubs:field>
        <pubs:field name="volume" type="text" display-name="Volume">
          <pubs:text>9</pubs:text>
        </pubs:field>
      </pubs:native>
    </pubs:bibliographic-data>
  </entry>
  <entry>
    <id>tag:elements@emory/publication/873965/bib-record/crossref</id>
    <pubs:data-source>
      <pubs:source-name>crossref</pubs:source-name>
      <pubs:id-at-source>10.1371/journal.pone.0096165</pubs:id-at-source>
    </pubs:data-source>
    <pubs:verification-status>unverified</pubs:verification-status>
    <category scheme="http://www.symplectic.co.uk/publications/atom-terms/1.0" term="http://www.symplectic.co.uk/publications/atom-terms/1.0/publication-bib-record" label="Publication Bibliographic Record" />
    <author>
      <name>EK Waller</name>
    </author>
    <title>
Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice</title>
    <updated>2014-09-04T12:28:06.427-04:00</updated>
    <pubs:bibliographic-data format="native">
      <pubs:native>
        <pubs:field name="authors" type="person-list" display-name="Authors">
          <pubs:people>
            <pubs:person>
              <pubs:last-name>Hossain</pubs:last-name>
              <pubs:initials>MS</pubs:initials>
            </pubs:person>
            <pubs:person>
              <pubs:last-name>Ramachandiran</pubs:last-name>
              <pubs:initials>S</pubs:initials>
            </pubs:person>
            <pubs:person>
              <pubs:last-name>Gewirtz</pubs:last-name>
              <pubs:initials>AT</pubs:initials>
            </pubs:person>
            <pubs:person>
              <pubs:last-name>Waller</pubs:last-name>
              <pubs:initials>EK</pubs:initials>
            </pubs:person>
          </pubs:people>
        </pubs:field>
        <pubs:field name="doi" type="text" display-name="DOI">
          <pubs:text>10.1371/journal.pone.0096165</pubs:text>
        </pubs:field>
        <pubs:field name="editors" type="person-list" display-name="Editors">
          <pubs:people>
            <pubs:person>
              <pubs:last-name>Heimesaat</pubs:last-name>
              <pubs:initials>MM</pubs:initials>
            </pubs:person>
          </pubs:people>
        </pubs:field>
        <pubs:field name="eissn" type="text" display-name="eISSN">
          <pubs:text>1932-6203</pubs:text>
        </pubs:field>
        <pubs:field name="issue" type="text" display-name="Issue">
          <pubs:text>5</pubs:text>
        </pubs:field>
        <pubs:field name="journal" type="text" display-name="Journal">
          <pubs:text>PLoS ONE</pubs:text>
        </pubs:field>
        <pubs:field name="language" type="text" display-name="Language">
          <pubs:text>aa</pubs:text>
        </pubs:field>
        <pubs:field name="pagination" type="pagination" display-name="Pagination">
          <pubs:pagination>
            <pubs:begin-page>e96165</pubs:begin-page>
            <pubs:end-page>e96170</pubs:end-page>
          </pubs:pagination>
        </pubs:field>
        <pubs:field name="publication-date" type="date" display-name="Publication date">
          <pubs:date>
            <pubs:day>30</pubs:day>
            <pubs:month>5</pubs:month>
            <pubs:year>2014</pubs:year>
          </pubs:date>
        </pubs:field>
        <pubs:field name="title" type="text" display-name="Title">
          <pubs:text>
Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice</pubs:text>
        </pubs:field>
        <pubs:field name="volume" type="text" display-name="Volume">
          <pubs:text>9</pubs:text>
        </pubs:field>
      </pubs:native>
    </pubs:bibliographic-data>
  </entry>
</feed>
